Nutritional Supplements Manufacturing in the UK Market Size, Trends & Growth Opportunity By Product Category, By Manufacturing Model, By Certification, By Customer Type, By Region and Forecast Till 2030

Report ID : AMR1006071 | Industries : Healthcare | Published On :September 2026 | Page Count : 277

Request Sample
Ask for Customization

Nutritional Supplements Manufacturing Market Overview and Definition

The UK nutritional supplements manufacturing market covers contract manufacturing, private label development and related product development and packaging services supplied to supplement brands across England, Scotland, Wales and Northern Ireland.

This report describes vitamins, minerals, sports nutrition and functional health supplement categories strictly as market segments manufactured for brand customers, and it makes no claim of health outcome, efficacy or clinical benefit for any product, ingredient or company covered on these pages.

Six segmentation dimensions structure this report, spanning fifty-eight named categories in total, and the first describes what is actually manufactured: eighteen product categories, from core vitamins, minerals and multivitamins through condition-specific categories such as immune health, cognitive health and joint and bone health supplements, to sports nutrition, herbal and botanical, and specialty nutraceutical categories.

Ten dosage form categories complete the product picture, spanning tablets, capsules, softgels, powders, gummies, liquids, sachets and stick packs, effervescent formats, chewables and functional shots.

Manufacturing model is the second dimension, spanning six categories: contract manufacturing, private label manufacturing, white label manufacturing, custom formulation development, end-to-end product development services, and packaging and fulfilment services.

The most useful commercial observation about this market is that formulation ownership, not the manufacturing model label alone, is what actually separates these six categories from a brand's point of view.

Certification and compliance category is the third dimension, spanning eight named categories including Good Manufacturing Practice (GMP) certified products, Medicines and Healthcare products Regulatory Agency (MHRA) compliant manufacturing, vegan, organic, halal and kosher certified products, allergen-free products and clean label products.

Customer type spans ten categories, from supplement brands and wellness brands through healthcare companies, pharmacy chains, retail private labels, direct-to-consumer brands, e-commerce brands and practitioner-led brands to international brand owners, and distribution strategy served completes the segmentation across six categories including retail-oriented, pharmacy-oriented, online-first, subscription-based, practitioner and clinical, and export-focused product lines.

This report covers nutritional supplements manufacturing, contract manufacturing, private label development and related product development and packaging services supplied across the United Kingdom.

It excludes finished-goods retail sales and marketing activity by supplement brands themselves, pharmaceutical drug manufacturing, and non-nutritional consumer wellness products outside this report's nutritional supplements manufacturing scope.

Buyer intelligence in the full report maps established supplement brands, emerging wellness startups, retail private label operators, pharmacy and healthcare companies and direct-to-consumer nutrition companies across England, Scotland, Wales and Northern Ireland, including a dedicated strategic relevance assessment for IVC Brunel Healthcare Limited.

Competitive benchmarking compares manufacturers across market presence, manufacturing capacity, product breadth, formulation expertise and four further metrics without disclosing proprietary competitive positioning data.

Market Size & Growth Forecast (2026 to 2030)

The UK nutritional supplements manufacturing market is estimated at approximately USD 3.4 Billion in 2025 and is projected to reach approximately USD 6.0 Billion by 2030, expanding at a compound annual growth rate of roughly 12.0 percent.

The estimate covers contract manufacturing, private label development and related product development and packaging services, and excludes finished-goods retail sales and marketing activity carried out by supplement brands themselves.

Vitamins, minerals and multivitamins together account for the largest product category by revenue, while functional mushroom and cognitive health supplements together form a fast-growing product category tied to emerging health trends.

Tablets and capsules together account for the largest dosage form category by volume, and gummies and functional shots form a fast-growing dosage form category tied to on-the-go and palatability-led consumption.

Contract manufacturing accounts for the largest manufacturing model category, reflecting how many UK supplement brands, particularly newer and direct-to-consumer brands, outsource production rather than build owned capacity, while private label manufacturing and custom formulation development together form a fast-growing manufacturing model category.

GMP certified products account for the largest certification category, reflecting its position as a near-universal baseline requirement, and vegan certified and allergen-free products together form a fast-growing certification category.

Supplement brands and wellness brands together account for the largest customer type category, and direct-to-consumer brands and e-commerce brands together form a fast-growing customer type category.

Retail-oriented products account for the largest distribution strategy category, and online-first and subscription-based nutrition brands together form a fast-growing distribution strategy category.

England accounts for the largest regional concentration in this report, and Scotland, Wales and Northern Ireland together form a smaller but steadily growing regional concentration.

The forecast assumes UK health and wellness consumer demand and private label retail investment continue broadly on recent trends, and a material shift in either would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 3.4 Billion
Forecast Size (2030)Approximately USD 6.0 Billion
CAGR (2025-2030)Approximately 12.0%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteContract manufacturing, private label development and related product development and packaging services only; excludes finished-goods retail sales by supplement brands
Largest Product CategoryVitamins, minerals and multivitamins
Fastest-Growing Product CategoryFunctional mushroom and cognitive health supplements
Largest Manufacturing ModelContract manufacturing
Fastest-Growing Manufacturing ModelPrivate label manufacturing and custom formulation development
Largest Certification CategoryGMP certified products
Largest Regional ConcentrationEngland

Market Drivers

Rising new product launch and category expansion activity across UK supplement brands, driving demand for contract manufacturing and private label development capacity.

Regulatory change activity and rising MHRA-compliant manufacturing requirements, prompting brands to favour manufacturers with established regulatory compliance and certification portfolios.

Growth in personalised nutrition and AI-assisted formulation development, reshaping how supplement brands approach product development services.

Expansion of online-first, subscription-based and export-focused distribution strategies, widening the addressable market for UK contract manufacturers.

Rising demand for condition-specific health supplement categories, including immune health, cognitive health and joint and bone health, broadening the product range manufacturers must support.

Growth in direct-to-consumer and e-commerce brand formation, which typically enters the market through outsourced contract or private label manufacturing rather than owned production.

Increasing retailer appetite for retail private label supplement ranges, extending private label programmes beyond specialist wellness brands into mainstream grocery and pharmacy retail.

Growing international brand owner interest in UK-based manufacturing capacity, tied to the UK's established regulatory reputation and export documentation infrastructure.

Rising demand for functional formats such as gummies, functional shots and effervescent products, requiring manufacturers to expand dosage form capability beyond traditional tablets and capsules.

Market Restraints

Regulatory risk tied to evolving UK supplement regulations, labelling requirements and health claim compliance, which manufacturers must continuously track.

Ingredient supply risk, reflecting raw material cost dynamics and dependence on global supplement ingredient supply chains.

Pricing pressure across manufacturing economics and packaging costs, compressing margin structure for contract manufacturers.

Competitive intensity between large integrated contract manufacturers, innovation-focused Contract Development and Manufacturing Organisation (CDMO) providers, private label specialists and premium nutraceutical manufacturing partners, fragmenting customer preference.

Certification stacking requirements, since brands increasingly request several certifications simultaneously, which raises the qualification burden on manufacturers relative to single-certification requests.

Long lead times for custom formulation development projects, which can affect a manufacturer's competitive position on accelerated brand launch schedules.

Skilled formulation and regulatory affairs personnel availability constraints, which can affect both new product development and ongoing customer technical support capacity.

Fragmented demand across smaller emerging wellness startups, which raises the cost of serving that segment commercially relative to established enterprise brands.

Extended quality assurance and batch documentation expectations from healthcare and pharmacy channel customers, which add ongoing commercial obligations beyond initial product launch.

PROCUREMENT INSIGHT

Brands increasingly qualify a manufacturer against several certifications at once rather than one at a time, meaning certification stacking now functions as a genuine screening filter on the supplier shortlist rather than a late-stage formality.

 

Market Opportunities

Considerable untapped opportunity identified in the report competitive mapping.

Underpenetrated buyer segments and emerging health trends, including functional mushroom supplements and cognitive health categories, identified in the report competitive mapping.

Premium manufacturing opportunities identified in the report competitive mapping, particularly across specialty nutraceutical categories.

Growth in export-focused product lines, supported by growing international brand owner demand for UK-based contract manufacturing capacity.

Underserved demand in personalised nutrition and functional format development, where fewer manufacturers have established deep formulation expertise.

Expansion of certification portfolios spanning vegan, organic, allergen-free and clean label categories together, which several manufacturers are using to differentiate from single-certification competitors.

Growth in subscription-based nutrition brand partnerships, tied to the wider expansion of subscription and online-first distribution strategies.

Multi-capability manufacturing capacity spanning contract, private label and custom formulation work, which reduces the number of separate supplier relationships a growing brand must maintain.

MARKET SHIFT

Personalised nutrition and functional format development remain underserved by manufacturers with deep formulation expertise even as cognitive health and functional mushroom categories rank among this market's fastest-growing product categories, leaving a formulation-support gap that AI-assisted development tools are only beginning to close.

 

Product Categories and Dosage Forms

Brands scoping a new supplement line increasingly weigh dosage form flexibility alongside health category positioning, since the eighteen nutritional supplement product categories tracked in this report, from vitamins and minerals through sports nutrition and specialty nutraceuticals, are each manufactured across ten distinct dosage form categories spanning tablets to functional shots.

Manufacturing Models: Contract, Private Label and Beyond

Contract manufacturing, private label manufacturing, white label manufacturing, custom formulation development, end-to-end product development services and packaging and fulfilment services each carry a different formulation ownership arrangement, and a brand's choice among these nutritional supplement contract manufacturing routes generally shapes its commercial relationship with a UK manufacturer more than any other single decision.

Certification and Compliance Standards

GMP certified, MHRA-compliant, vegan, organic, halal, kosher, allergen-free and clean label categories together define which manufacturers a brand can shortlist, and this spread of nutritional supplement certification standards increasingly determines market access before any commercial negotiation begins.

Customer Types and Distribution Strategies

Supplement brands, wellness brands, sports nutrition brands, healthcare companies, pharmacy chains, retail private labels, direct-to-consumer brands, e-commerce brands, practitioner-led brands and international brand owners route their products through retail, pharmacy, online-first, subscription, practitioner and export-focused strategies, and this mix of nutritional supplement brand customer types varies considerably by how a brand ultimately reaches its end consumer.

Nutritional Supplements Manufacturing Market, By Region

This report covers England, Scotland, Wales and Northern Ireland, reflecting where UK nutritional supplements manufacturing capacity and brand demand are concentrated.

England accounts for the largest regional concentration in this report, covered through London, Surrey, Hertfordshire, Cambridgeshire, Greater Manchester, West Midlands and Yorkshire, with manufacturing and brand activity concentrated around London and the wider South East, the East of England, and established Midlands and Northern manufacturing clusters.

Scotland represents a smaller but steadily growing regional concentration, covered through Glasgow and Edinburgh, with demand tied to wellness and sports nutrition brand activity.

Wales and Northern Ireland, covered through Cardiff, Newport and Belfast respectively, each represent an emerging regional concentration within this report's overall United Kingdom scope.

Regional sizing, growth rates and county-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Scotland's wellness and sports nutrition brand base is growing from a smaller manufacturing footprint than England's established clusters, leaving capacity headroom for manufacturers willing to build closer commercial relationships outside the South East.

 

Leading Companies

IVC Brunel Healthcare Limited, Bee Health Limited, Principle Healthcare Group, NutraPak UK, Laleham Health & Beauty, Rain Nutrience, PharmaPac UK, BHP Laboratories, Nutra Manufacturing, Orange County CBD, Supplement Factory UK, Cambridge Commodities Manufacturing Solutions, EuroCaps Ltd, The Protein Works Manufacturing Division, HealthAid Ltd, Probiotics International (Protexin) and Aesica Pharmaceuticals are covered in the full report. An introduction to the supplier landscape by company type is available on the UK nutritional supplement manufacturers page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how UK nutritional supplements manufacturing capacity is actually won.

Buyer intelligence maps the buyer ecosystem across established supplement brands, emerging wellness startups, retail private label operators, pharmacy and healthcare companies and direct-to-consumer nutrition companies in full, including a dedicated strategic relevance assessment for IVC Brunel Healthcare Limited.

Decision-making structure coverage spans vendor selection criteria, contract value bands, sales cycle assessment and the roles typically involved in a manufacturer selection decision.

Competitive benchmarking compares manufacturers across manufacturing capacity, product breadth, formulation expertise, certification coverage and export reach.

The market playbook covers raw material cost dynamics, manufacturing economics, UK supplement regulations and personalised nutrition and AI-assisted formulation development.

Pricing and procurement chapters cover product development cost analysis, manufacturing cost analysis, supplier concentration and total cost of ownership analysis.

Go-to-market chapters set out new category entry, private label expansion, export growth strategy, and nutraceutical business events and health ingredient exhibitions.

Company profiles cover seventeen manufacturers across manufacturing facilities, product and service portfolio, quality certifications and compliance standards, and research and development capabilities.

Frequently Asked Questions

The market is estimated at approximately USD 3.4 Billion in 2025 and is projected to reach approximately USD 6.0 Billion by 2030, expanding at a compound annual growth rate of roughly 12.0 percent.

Contract manufacturing, private label development and related product development and packaging services supplied to supplement brands, covering vitamins, minerals, sports nutrition and functional health supplement categories described strictly as market segments.

Rising new product launch and category expansion activity across UK supplement brands is the leading driver, alongside rising MHRA-compliant manufacturing requirements and growth in personalised nutrition and AI-assisted formulation development.

England accounts for the largest regional concentration, covered through London, Surrey, Hertfordshire, Cambridgeshire, Greater Manchester, West Midlands and Yorkshire, with Scotland, Wales and Northern Ireland forming smaller but steadily growing concentrations.

Both are manufacturing model categories tracked in this report, distinguished chiefly by formulation ownership: private label products are generally built from a manufacturer's existing formulations, while contract manufacturing more often involves a brand-supplied or jointly developed formula.

GMP certified and MHRA-compliant manufacturing form the largest certification category, with vegan, organic, halal, kosher, allergen-free and clean label certifications increasingly requested alongside them rather than in isolation.

Vitamins, minerals and multivitamins together account for the largest product category by revenue, while functional mushroom and cognitive health supplements together form a fast-growing category tied to emerging health trends.

IVC Brunel Healthcare Limited, Bee Health Limited, Principle Healthcare Group and fourteen further manufacturers are covered in the full report, spanning large integrated contract manufacturers, private label specialists and premium nutraceutical manufacturing partners.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Nutritional Supplements Manufacturing in the UK Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Rising New Product Launch and Category Expansion Activity Across UK Supplement Brands, Driving Demand for Contract Manufacturing and Private Label Development Capacity.

3.3.2. Regulatory Change Activity and Rising MHRA-Compliant Manufacturing Requirements, Prompting Brands to Favour Manufacturers with Established Regulatory Compliance and Certification Portfolios.

3.3.3. Growth in Personalised Nutrition and AI-Assisted Formulation Development, Reshaping How Supplement Brands Approach Product Development Services.

3.3.4. Expansion of Online-First, Subscription-Based and Export-Focused Distribution Strategies, Widening the Addressable Market for UK Contract Manufacturers.

3.4. Restraints

3.4.1. Regulatory Risk Tied to Evolving UK Supplement Regulations, Labelling Requirements and Health Claim Compliance, Which Manufacturers Must Continuously Track.

3.4.2. Ingredient Supply Risk, Reflecting Raw Material Cost Dynamics and Dependence on Global Supplement Ingredient Supply Chains.

3.4.3. Pricing Pressure Across Manufacturing Economics and Packaging Costs, Compressing Margin Structure for Contract Manufacturers.

3.4.4. Competitive Intensity Between Large Integrated Contract Manufacturers, Innovation-Focused CDMO Providers, Private Label Specialists and Premium Nutraceutical Manufacturing Partners, Fragmenting Customer Preference.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report Competitive Mapping.

3.5.2. Underpenetrated Buyer Segments and Emerging Health Trends, Including Functional Mushroom Supplements and Cognitive Health Categories, Identified in the Report Competitive Mapping.

3.5.3. Premium Manufacturing Opportunities Identified in the Report Competitive Mapping, Particularly Across Specialty Nutraceutical Categories.

3.5.4. Growth in Export-Focused Product Lines, Supported by Growing International Brand Owner Demand for UK-Based Contract Manufacturing Capacity.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Product Category

4.1. Vitamins

4.2. Minerals

4.3. Multivitamins

4.4. Omega-3 and Essential Fatty Acids

4.5. Probiotics and Gut Health Supplements

4.6. Sports Nutrition Supplements

4.7. Protein Supplements

4.8. Weight Management Supplements

4.9. Immune Health Supplements

4.10. Cognitive Health Supplements

4.11. Joint and Bone Health Supplements

4.12. Women's Health Supplements

4.13. Men's Health Supplements

4.14. Children's Supplements

4.15. Healthy Ageing Supplements

4.16. Herbal and Botanical Supplements

4.17. Functional Mushroom Supplements

4.18. Specialty Nutraceuticals

5. Dosage Form

5.1. Tablets

5.2. Capsules

5.3. Softgels

5.4. Powders

5.5. Gummies

5.6. Liquids

5.7. Sachets and Stick Packs

5.8. Effervescent Formats

5.9. Chewables

5.10. Functional Shots

6. Manufacturing Model

6.1. Contract Manufacturing

6.2. Private Label Manufacturing

6.3. White Label Manufacturing

6.4. Custom Formulation Development

6.5. End-to-End Product Development Services

6.6. Packaging and Fulfilment Services

7. Certification and Compliance Category

7.1. GMP Certified Products

7.2. MHRA-Compliant Manufacturing

7.3. Vegan Certified Products

7.4. Organic Certified Products

7.5. Halal Certified Products

7.6. Kosher Certified Products

7.7. Allergen-Free Products

7.8. Clean Label Products

8. Customer Type

8.1. Supplement Brands

8.2. Wellness Brands

8.3. Sports Nutrition Brands

8.4. Healthcare Companies

8.5. Pharmacy Chains

8.6. Retail Private Labels

8.7. Direct-to-Consumer Brands

8.8. E-Commerce Brands

8.9. Practitioner-Led Brands

8.10. International Brand Owners

9. Distribution Strategy Served

9.1. Retail-Oriented Products

9.2. Pharmacy-Oriented Products

9.3. Online-First Brands

9.4. Subscription-Based Nutrition Brands

9.5. Practitioner and Clinical Channels

9.6. Export-Focused Product Lines

10. Buyer Intelligence and Demand Landscape

10.1. Buyer Segmentation

10.1.1. Established Supplement Brands

10.1.2. Emerging Wellness Startups

10.1.3. Retail Private Label Operators

10.1.4. Pharmacy and Healthcare Companies

10.1.5. Sports Nutrition Brands

10.1.6. Direct-to-Consumer Nutrition Companies

10.2. Buyer Industry Mapping

10.2.1. Nutraceuticals

10.2.2. Healthcare

10.2.3. Wellness

10.2.4. Sports Performance

10.2.5. Functional Foods

10.2.6. Consumer Health

10.3. Buyer Company Size Analysis

10.3.1. Enterprise Brands

10.3.2. Mid-Market Brands

10.3.3. Growth-Stage Companies

10.3.4. Startup Brands

10.4. Regional Demand Clusters

10.4.1. Southern England

10.4.2. Midlands

10.4.3. Northern England

10.4.4. Scotland

10.4.5. Wales

10.5. Procurement Models

10.5.1. Contract Manufacturing Agreements

10.5.2. Private Label Programmes

10.5.3. Long-Term Strategic Supply Partnerships

10.5.4. Project-Based Product Development

10.6. Buying Triggers

10.6.1. New Product Launches

10.6.2. Regulatory Changes

10.6.3. Capacity Constraints

10.6.4. Product Reformulation

10.6.5. Category Expansion

10.6.6. Export Market Entry

10.7. Decision-Making Structure

10.7.1. CEOs and Founders

10.7.2. Product Development Directors

10.7.3. Procurement Leaders

10.7.4. Innovation Managers

10.7.5. Regulatory Affairs Teams

10.7.6. Commercial Directors

10.8. Vendor Selection Criteria

10.8.1. Regulatory Compliance

10.8.2. Manufacturing Capacity

10.8.3. Formulation Expertise

10.8.4. Certification Portfolio

10.8.5. Speed-to-Market

10.8.6. Cost Competitiveness

10.8.7. Innovation Capabilities

10.9. Contract Value Bands

10.9.1. Pilot Manufacturing Programmes

10.9.2. SME Manufacturing Contracts

10.9.3. Mid-Scale Commercial Contracts

10.9.4. Strategic Enterprise Agreements

10.10. Sales Cycle Assessment

10.10.1. Startup Projects

10.10.2. Brand Expansion Projects

10.10.3. Retail Launch Programmes

10.10.4. Multi-Year Manufacturing Partnerships

10.11. Strategic Relevance for IVC Brunel

10.11.1. Strategic Relevance for IVC Brunel

11. United Kingdom Market Analysis and Forecast (2026–2030)

11.1. Introduction

11.2. Market Share Analysis

11.3. Market Size and Forecast

11.4. Market Size and Forecast, By Geography

11.4.1. England

11.4.1.1. Market Share Analysis

11.4.1.2. Market Size and Forecast

11.4.1.3. By Product

11.4.1.4. By Technology

11.4.1.5. By Application

11.4.1.6. By Customer

11.4.1.7. London

11.4.1.7.1. Market Share Analysis

11.4.1.7.2. Market Size and Forecast

11.4.1.7.3. By Product

11.4.1.7.4. By Technology

11.4.1.7.5. By Application

11.4.1.7.6. By Customer

11.4.1.8. Surrey

11.4.1.8.1. Market Share Analysis

11.4.1.8.2. Market Size and Forecast

11.4.1.8.3. By Product

11.4.1.8.4. By Technology

11.4.1.8.5. By Application

11.4.1.8.6. By Customer

11.4.1.9. Hertfordshire

11.4.1.9.1. Market Share Analysis

11.4.1.9.2. Market Size and Forecast

11.4.1.9.3. By Product

11.4.1.9.4. By Technology

11.4.1.9.5. By Application

11.4.1.9.6. By Customer

11.4.1.10. Cambridgeshire

11.4.1.10.1. Market Share Analysis

11.4.1.10.2. Market Size and Forecast

11.4.1.10.3. By Product

11.4.1.10.4. By Technology

11.4.1.10.5. By Application

11.4.1.10.6. By Customer

11.4.1.11. Greater Manchester

11.4.1.11.1. Market Share Analysis

11.4.1.11.2. Market Size and Forecast

11.4.1.11.3. By Product

11.4.1.11.4. By Technology

11.4.1.11.5. By Application

11.4.1.11.6. By Customer

11.4.1.12. West Midlands

11.4.1.12.1. Market Share Analysis

11.4.1.12.2. Market Size and Forecast

11.4.1.12.3. By Product

11.4.1.12.4. By Technology

11.4.1.12.5. By Application

11.4.1.12.6. By Customer

11.4.1.13. Yorkshire

11.4.1.13.1. Market Share Analysis

11.4.1.13.2. Market Size and Forecast

11.4.1.13.3. By Product

11.4.1.13.4. By Technology

11.4.1.13.5. By Application

11.4.1.13.6. By Customer

11.4.2. Scotland

11.4.2.1. Market Share Analysis

11.4.2.2. Market Size and Forecast

11.4.2.3. By Product

11.4.2.4. By Technology

11.4.2.5. By Application

11.4.2.6. By Customer

11.4.2.7. Glasgow

11.4.2.7.1. Market Share Analysis

11.4.2.7.2. Market Size and Forecast

11.4.2.7.3. By Product

11.4.2.7.4. By Technology

11.4.2.7.5. By Application

11.4.2.7.6. By Customer

11.4.2.8. Edinburgh

11.4.2.8.1. Market Share Analysis

11.4.2.8.2. Market Size and Forecast

11.4.2.8.3. By Product

11.4.2.8.4. By Technology

11.4.2.8.5. By Application

11.4.2.8.6. By Customer

11.4.3. Wales

11.4.3.1. Market Share Analysis

11.4.3.2. Market Size and Forecast

11.4.3.3. By Product

11.4.3.4. By Technology

11.4.3.5. By Application

11.4.3.6. By Customer

11.4.3.7. Cardiff

11.4.3.7.1. Market Share Analysis

11.4.3.7.2. Market Size and Forecast

11.4.3.7.3. By Product

11.4.3.7.4. By Technology

11.4.3.7.5. By Application

11.4.3.7.6. By Customer

11.4.3.8. Newport

11.4.3.8.1. Market Share Analysis

11.4.3.8.2. Market Size and Forecast

11.4.3.8.3. By Product

11.4.3.8.4. By Technology

11.4.3.8.5. By Application

11.4.3.8.6. By Customer

11.4.4. Northern Ireland

11.4.4.1. Market Share Analysis

11.4.4.2. Market Size and Forecast

11.4.4.3. By Product

11.4.4.4. By Technology

11.4.4.5. By Application

11.4.4.6. By Customer

11.4.4.7. Belfast

11.4.4.7.1. Market Share Analysis

11.4.4.7.2. Market Size and Forecast

11.4.4.7.3. By Product

11.4.4.7.4. By Technology

11.4.4.7.5. By Application

11.4.4.7.6. By Customer

12. Competition Analysis

12.1. Market Positioning Overview

12.1.1. Large Integrated Contract Manufacturers

12.1.2. Innovation-Focused CDMO Providers

12.1.3. Private Label Specialists

12.1.4. Premium Nutraceutical Manufacturing Partners

12.1.5. High-Volume Production Specialists

12.2. Competitive Benchmarking Metrics

12.2.1. Market Presence

12.2.2. Manufacturing Capacity

12.2.3. Product Breadth

12.2.4. Formulation Expertise

12.2.5. Certification Coverage

12.2.6. Innovation Capabilities

12.2.7. Export Reach

12.2.8. Customer Portfolio Strength

12.3. Strategic Moves

12.3.1. Capacity Expansions

12.3.2. Facility Investments

12.3.3. Product Innovation Initiatives

12.3.4. Partnership Agreements

12.3.5. Certification Additions

12.3.6. International Expansion Activities

12.3.7. Technology Investments

12.4. Competitive Mapping & Gaps

12.4.1. Considerable Untapped Opportunity

12.4.2. Underpenetrated Buyer Segments

12.4.3. Emerging Health Trends

12.4.4. Premium Manufacturing Opportunities

12.4.5. Export Market Gaps

12.4.6. Differentiation Opportunities for IVC Brunel

13. Company Profiles

13.1. IVC Brunel Healthcare Limited

13.1.1. Company Overview

13.1.2. Headquarters

13.1.3. Ownership Structure

13.1.4. Founding Year

13.1.5. Workforce

13.1.6. Geographic Footprint

13.1.7. Manufacturing Facilities

13.1.8. Product and Service Portfolio

13.1.9. Dosage Form Capabilities

13.1.10. Target Customer Segments

13.1.11. Distribution and Go-to-Market Model

13.1.12. Key Financial Information

13.1.13. Quality Certifications and Compliance Standards

13.1.14. Strategic Partnerships and Alliances

13.1.15. Research and Development Capabilities

13.1.16. Innovation Pipeline

13.1.17. Recent Developments

13.1.18. SWOT Snapshot

13.2. Bee Health Limited

13.2.1. Company Overview

13.2.2. Headquarters

13.2.3. Ownership Structure

13.2.4. Founding Year

13.2.5. Workforce

13.2.6. Geographic Footprint

13.2.7. Manufacturing Facilities

13.2.8. Product and Service Portfolio

13.2.9. Dosage Form Capabilities

13.2.10. Target Customer Segments

13.2.11. Distribution and Go-to-Market Model

13.2.12. Key Financial Information

13.2.13. Quality Certifications and Compliance Standards

13.2.14. Strategic Partnerships and Alliances

13.2.15. Research and Development Capabilities

13.2.16. Innovation Pipeline

13.2.17. Recent Developments

13.2.18. SWOT Snapshot

13.3. Principle Healthcare Group

13.3.1. Company Overview

13.3.2. Headquarters

13.3.3. Ownership Structure

13.3.4. Founding Year

13.3.5. Workforce

13.3.6. Geographic Footprint

13.3.7. Manufacturing Facilities

13.3.8. Product and Service Portfolio

13.3.9. Dosage Form Capabilities

13.3.10. Target Customer Segments

13.3.11. Distribution and Go-to-Market Model

13.3.12. Key Financial Information

13.3.13. Quality Certifications and Compliance Standards

13.3.14. Strategic Partnerships and Alliances

13.3.15. Research and Development Capabilities

13.3.16. Innovation Pipeline

13.3.17. Recent Developments

13.3.18. SWOT Snapshot

13.4. NutraPak UK

13.4.1. Company Overview

13.4.2. Headquarters

13.4.3. Ownership Structure

13.4.4. Founding Year

13.4.5. Workforce

13.4.6. Geographic Footprint

13.4.7. Manufacturing Facilities

13.4.8. Product and Service Portfolio

13.4.9. Dosage Form Capabilities

13.4.10. Target Customer Segments

13.4.11. Distribution and Go-to-Market Model

13.4.12. Key Financial Information

13.4.13. Quality Certifications and Compliance Standards

13.4.14. Strategic Partnerships and Alliances

13.4.15. Research and Development Capabilities

13.4.16. Innovation Pipeline

13.4.17. Recent Developments

13.4.18. SWOT Snapshot

13.5. Laleham Health & Beauty

13.5.1. Company Overview

13.5.2. Headquarters

13.5.3. Ownership Structure

13.5.4. Founding Year

13.5.5. Workforce

13.5.6. Geographic Footprint

13.5.7. Manufacturing Facilities

13.5.8. Product and Service Portfolio

13.5.9. Dosage Form Capabilities

13.5.10. Target Customer Segments

13.5.11. Distribution and Go-to-Market Model

13.5.12. Key Financial Information

13.5.13. Quality Certifications and Compliance Standards

13.5.14. Strategic Partnerships and Alliances

13.5.15. Research and Development Capabilities

13.5.16. Innovation Pipeline

13.5.17. Recent Developments

13.5.18. SWOT Snapshot

13.6. Rain Nutrience

13.6.1. Company Overview

13.6.2. Headquarters

13.6.3. Ownership Structure

13.6.4. Founding Year

13.6.5. Workforce

13.6.6. Geographic Footprint

13.6.7. Manufacturing Facilities

13.6.8. Product and Service Portfolio

13.6.9. Dosage Form Capabilities

13.6.10. Target Customer Segments

13.6.11. Distribution and Go-to-Market Model

13.6.12. Key Financial Information

13.6.13. Quality Certifications and Compliance Standards

13.6.14. Strategic Partnerships and Alliances

13.6.15. Research and Development Capabilities

13.6.16. Innovation Pipeline

13.6.17. Recent Developments

13.6.18. SWOT Snapshot

13.7. PharmaPac UK

13.7.1. Company Overview

13.7.2. Headquarters

13.7.3. Ownership Structure

13.7.4. Founding Year

13.7.5. Workforce

13.7.6. Geographic Footprint

13.7.7. Manufacturing Facilities

13.7.8. Product and Service Portfolio

13.7.9. Dosage Form Capabilities

13.7.10. Target Customer Segments

13.7.11. Distribution and Go-to-Market Model

13.7.12. Key Financial Information

13.7.13. Quality Certifications and Compliance Standards

13.7.14. Strategic Partnerships and Alliances

13.7.15. Research and Development Capabilities

13.7.16. Innovation Pipeline

13.7.17. Recent Developments

13.7.18. SWOT Snapshot

13.8. BHP Laboratories

13.8.1. Company Overview

13.8.2. Headquarters

13.8.3. Ownership Structure

13.8.4. Founding Year

13.8.5. Workforce

13.8.6. Geographic Footprint

13.8.7. Manufacturing Facilities

13.8.8. Product and Service Portfolio

13.8.9. Dosage Form Capabilities

13.8.10. Target Customer Segments

13.8.11. Distribution and Go-to-Market Model

13.8.12. Key Financial Information

13.8.13. Quality Certifications and Compliance Standards

13.8.14. Strategic Partnerships and Alliances

13.8.15. Research and Development Capabilities

13.8.16. Innovation Pipeline

13.8.17. Recent Developments

13.8.18. SWOT Snapshot

13.9. Nutra Manufacturing

13.9.1. Company Overview

13.9.2. Headquarters

13.9.3. Ownership Structure

13.9.4. Founding Year

13.9.5. Workforce

13.9.6. Geographic Footprint

13.9.7. Manufacturing Facilities

13.9.8. Product and Service Portfolio

13.9.9. Dosage Form Capabilities

13.9.10. Target Customer Segments

13.9.11. Distribution and Go-to-Market Model

13.9.12. Key Financial Information

13.9.13. Quality Certifications and Compliance Standards

13.9.14. Strategic Partnerships and Alliances

13.9.15. Research and Development Capabilities

13.9.16. Innovation Pipeline

13.9.17. Recent Developments

13.9.18. SWOT Snapshot

13.10. Orange County CBD

13.10.1. Company Overview

13.10.2. Headquarters

13.10.3. Ownership Structure

13.10.4. Founding Year

13.10.5. Workforce

13.10.6. Geographic Footprint

13.10.7. Manufacturing Facilities

13.10.8. Product and Service Portfolio

13.10.9. Dosage Form Capabilities

13.10.10. Target Customer Segments

13.10.11. Distribution and Go-to-Market Model

13.10.12. Key Financial Information

13.10.13. Quality Certifications and Compliance Standards

13.10.14. Strategic Partnerships and Alliances

13.10.15. Research and Development Capabilities

13.10.16. Innovation Pipeline

13.10.17. Recent Developments

13.10.18. SWOT Snapshot

13.11. Supplement Factory UK

13.11.1. Company Overview

13.11.2. Headquarters

13.11.3. Ownership Structure

13.11.4. Founding Year

13.11.5. Workforce

13.11.6. Geographic Footprint

13.11.7. Manufacturing Facilities

13.11.8. Product and Service Portfolio

13.11.9. Dosage Form Capabilities

13.11.10. Target Customer Segments

13.11.11. Distribution and Go-to-Market Model

13.11.12. Key Financial Information

13.11.13. Quality Certifications and Compliance Standards

13.11.14. Strategic Partnerships and Alliances

13.11.15. Research and Development Capabilities

13.11.16. Innovation Pipeline

13.11.17. Recent Developments

13.11.18. SWOT Snapshot

13.12. Cambridge Commodities Manufacturing Solutions

13.12.1. Company Overview

13.12.2. Headquarters

13.12.3. Ownership Structure

13.12.4. Founding Year

13.12.5. Workforce

13.12.6. Geographic Footprint

13.12.7. Manufacturing Facilities

13.12.8. Product and Service Portfolio

13.12.9. Dosage Form Capabilities

13.12.10. Target Customer Segments

13.12.11. Distribution and Go-to-Market Model

13.12.12. Key Financial Information

13.12.13. Quality Certifications and Compliance Standards

13.12.14. Strategic Partnerships and Alliances

13.12.15. Research and Development Capabilities

13.12.16. Innovation Pipeline

13.12.17. Recent Developments

13.12.18. SWOT Snapshot

13.13. EuroCaps Ltd

13.13.1. Company Overview

13.13.2. Headquarters

13.13.3. Ownership Structure

13.13.4. Founding Year

13.13.5. Workforce

13.13.6. Geographic Footprint

13.13.7. Manufacturing Facilities

13.13.8. Product and Service Portfolio

13.13.9. Dosage Form Capabilities

13.13.10. Target Customer Segments

13.13.11. Distribution and Go-to-Market Model

13.13.12. Key Financial Information

13.13.13. Quality Certifications and Compliance Standards

13.13.14. Strategic Partnerships and Alliances

13.13.15. Research and Development Capabilities

13.13.16. Innovation Pipeline

13.13.17. Recent Developments

13.13.18. SWOT Snapshot

13.14. The Protein Works Manufacturing Division

13.14.1. Company Overview

13.14.2. Headquarters

13.14.3. Ownership Structure

13.14.4. Founding Year

13.14.5. Workforce

13.14.6. Geographic Footprint

13.14.7. Manufacturing Facilities

13.14.8. Product and Service Portfolio

13.14.9. Dosage Form Capabilities

13.14.10. Target Customer Segments

13.14.11. Distribution and Go-to-Market Model

13.14.12. Key Financial Information

13.14.13. Quality Certifications and Compliance Standards

13.14.14. Strategic Partnerships and Alliances

13.14.15. Research and Development Capabilities

13.14.16. Innovation Pipeline

13.14.17. Recent Developments

13.14.18. SWOT Snapshot

13.15. HealthAid Ltd

13.15.1. Company Overview

13.15.2. Headquarters

13.15.3. Ownership Structure

13.15.4. Founding Year

13.15.5. Workforce

13.15.6. Geographic Footprint

13.15.7. Manufacturing Facilities

13.15.8. Product and Service Portfolio

13.15.9. Dosage Form Capabilities

13.15.10. Target Customer Segments

13.15.11. Distribution and Go-to-Market Model

13.15.12. Key Financial Information

13.15.13. Quality Certifications and Compliance Standards

13.15.14. Strategic Partnerships and Alliances

13.15.15. Research and Development Capabilities

13.15.16. Innovation Pipeline

13.15.17. Recent Developments

13.15.18. SWOT Snapshot

13.16. Probiotics International (Protexin)

13.16.1. Company Overview

13.16.2. Headquarters

13.16.3. Ownership Structure

13.16.4. Founding Year

13.16.5. Workforce

13.16.6. Geographic Footprint

13.16.7. Manufacturing Facilities

13.16.8. Product and Service Portfolio

13.16.9. Dosage Form Capabilities

13.16.10. Target Customer Segments

13.16.11. Distribution and Go-to-Market Model

13.16.12. Key Financial Information

13.16.13. Quality Certifications and Compliance Standards

13.16.14. Strategic Partnerships and Alliances

13.16.15. Research and Development Capabilities

13.16.16. Innovation Pipeline

13.16.17. Recent Developments

13.16.18. SWOT Snapshot

13.17. Aesica Pharmaceuticals (Nutrition Operations where relevant)

13.17.1. Company Overview

13.17.2. Headquarters

13.17.3. Ownership Structure

13.17.4. Founding Year

13.17.5. Workforce

13.17.6. Geographic Footprint

13.17.7. Manufacturing Facilities

13.17.8. Product and Service Portfolio

13.17.9. Dosage Form Capabilities

13.17.10. Target Customer Segments

13.17.11. Distribution and Go-to-Market Model

13.17.12. Key Financial Information

13.17.13. Quality Certifications and Compliance Standards

13.17.14. Strategic Partnerships and Alliances

13.17.15. Research and Development Capabilities

13.17.16. Innovation Pipeline

13.17.17. Recent Developments

13.17.18. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 3.4 Billion in 2025 and is projected to reach approximately USD 6.0 Billion by 2030, expanding at a compound annual growth rate of roughly 12.0 percent.

Contract manufacturing, private label development and related product development and packaging services supplied to supplement brands, covering vitamins, minerals, sports nutrition and functional health supplement categories described strictly as market segments.

Rising new product launch and category expansion activity across UK supplement brands is the leading driver, alongside rising MHRA-compliant manufacturing requirements and growth in personalised nutrition and AI-assisted formulation development.

England accounts for the largest regional concentration, covered through London, Surrey, Hertfordshire, Cambridgeshire, Greater Manchester, West Midlands and Yorkshire, with Scotland, Wales and Northern Ireland forming smaller but steadily growing concentrations.

Both are manufacturing model categories tracked in this report, distinguished chiefly by formulation ownership: private label products are generally built from a manufacturer's existing formulations, while contract manufacturing more often involves a brand-supplied or jointly developed formula.

GMP certified and MHRA-compliant manufacturing form the largest certification category, with vegan, organic, halal, kosher, allergen-free and clean label certifications increasingly requested alongside them rather than in isolation.

Vitamins, minerals and multivitamins together account for the largest product category by revenue, while functional mushroom and cognitive health supplements together form a fast-growing category tied to emerging health trends.

IVC Brunel Healthcare Limited, Bee Health Limited, Principle Healthcare Group and fourteen further manufacturers are covered in the full report, spanning large integrated contract manufacturers, private label specialists and premium nutraceutical manufacturing partners.

Inquire Before Buying Request Free Sample Ask For Discount

Research Methodology

Nutritional supplements manufacturing separated from the finished-goods retail market

Nutritional supplements are frequently reported inside the much larger finished-goods dietary supplements retail market, which spans brand marketing, retail margin and consumer sales activity not comparable with the manufacturing-service revenue described here. This estimate covers contract manufacturing, private label development and related product development and packaging services only. The snapshot table states that boundary so the figure is not mistaken for anything larger.

Derivation from UK dietary supplements contract manufacturing revenue

Grand View Research's estimate of the UK dietary supplements contract manufacturing market at approximately USD 3,083 Million in 2024, growing at approximately 12 percent annually to approximately USD 6,077 Million by 2030, was taken as the primary anchor, since its definition of contract manufacturing aligns closely with this report's manufacturing-model segmentation spanning contract, private label, white label, custom formulation, end-to-end and packaging and fulfilment services.

Cross-checked against total UK vitamin and supplement manufacturing industry revenue

IBISWorld's UK Vitamin and Supplement Manufacturing industry estimate of approximately GBP 1.6 to 1.8 Billion (approximately USD 2.0 to 2.3 Billion) across 2024 to 2026 was used as a secondary cross-check of overall UK manufacturing industry scale. The gap between this figure and the larger contract manufacturing estimate reflects the contract manufacturing figure's broader inclusion of private label finished-goods value alongside pure contract-service fees, a definitional difference rather than a market signal.

Forecast basis and its principal sensitivity

Rolling the 2024 base forward at its own approximately 12 percent growth rate produces a 2025 base year of approximately USD 3.4 Billion and a 2030 figure of approximately USD 6.0 Billion. The forecast assumes UK health and wellness consumer demand and private label retail investment continue broadly on recent trends. Private label and direct-to-consumer brand growth pace is the material sensitivity, since these customer types most directly drive outsourced contract and private label manufacturing volume in this market.

Frequently Asked Questions

The market is estimated at approximately USD 3.4 Billion in 2025 and is projected to reach approximately USD 6.0 Billion by 2030, expanding at a compound annual growth rate of roughly 12.0 percent.

Contract manufacturing, private label development and related product development and packaging services supplied to supplement brands, covering vitamins, minerals, sports nutrition and functional health supplement categories described strictly as market segments.

Rising new product launch and category expansion activity across UK supplement brands is the leading driver, alongside rising MHRA-compliant manufacturing requirements and growth in personalised nutrition and AI-assisted formulation development.

England accounts for the largest regional concentration, covered through London, Surrey, Hertfordshire, Cambridgeshire, Greater Manchester, West Midlands and Yorkshire, with Scotland, Wales and Northern Ireland forming smaller but steadily growing concentrations.

Both are manufacturing model categories tracked in this report, distinguished chiefly by formulation ownership: private label products are generally built from a manufacturer's existing formulations, while contract manufacturing more often involves a brand-supplied or jointly developed formula.

GMP certified and MHRA-compliant manufacturing form the largest certification category, with vegan, organic, halal, kosher, allergen-free and clean label certifications increasingly requested alongside them rather than in isolation.

Vitamins, minerals and multivitamins together account for the largest product category by revenue, while functional mushroom and cognitive health supplements together form a fast-growing category tied to emerging health trends.

IVC Brunel Healthcare Limited, Bee Health Limited, Principle Healthcare Group and fourteen further manufacturers are covered in the full report, spanning large integrated contract manufacturers, private label specialists and premium nutraceutical manufacturing partners.

Inquire Before Buying Request Free Sample Ask For Discount